Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Yuya Hirasawa to Treatment Outcome

This is a "connection" page, showing publications Yuya Hirasawa has written about Treatment Outcome.

 
Connection Strength
 
 
 
0.248
 
  1. Hirasawa Y, Isobe J, Hosonuma M, Tsurui T, Baba Y, Funayama E, Tajima K, Murayama M, Narikawa Y, Toyoda H, Shida M, Sasaki A, Maruyama Y, Amari Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Sambe T, Uchida N, Wada S, Kobayashi S, Kiuchi Y, Kuramasu A, Yoshimura K, Tsunoda T. Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors. Front Immunol. 2025; 16:1528521.
    View in: PubMed
    Score: 0.081
  2. Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer Res. 2024 Aug; 44(8):3397-3407.
    View in: PubMed
    Score: 0.076
  3. Ariizumi H, Shimazui M, Ogawa C, Kaneki M, Saito N, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Shimokawa M, Ohkuma R, Kubota Y, Horiike A, Wada S, Yoshimura K, Murakami K, Tsunoda T. Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study. Front Immunol. 2025; 16:1640603.
    View in: PubMed
    Score: 0.021
  4. Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H, Yamochi T. Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Front Immunol. 2025; 16:1528594.
    View in: PubMed
    Score: 0.021
  5. Yamashita T, Fujimasa K, Otsuka K, Saito A, Kohmoto M, Motegi K, Ariyoshi T, Goto S, Yamochi T, Takimoto M, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T, Murakami M, Aoki T. Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma. Anticancer Res. 2025 May; 45(5):2051-2058.
    View in: PubMed
    Score: 0.020
  6. Ohkuma R, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Aoki T, Murakami M, Kobayashi S, Tsunoda T, Wada S. The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer. Pancreas. 2021 02 01; 50(2):167-175.
    View in: PubMed
    Score: 0.015
  7. Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res. 2019 Sep; 39(9):5195-5201.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)